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ABSTRACT 
Somatostatin (somatotropin release inhibitory factor; SRIF), is an endogenous 
peptide family that controls cellular secretion and proliferation. While SRIF's cognate 
receptors and associated actions have been clearly identified in a range of tissues, such as 
the endocrine, gastrointestinal and immune systems, a role in human lung physiology 
remains unknown. Using primary human bronchial smooth muscle cells (hBSMC) as a 
model for studying SRIF's actions, we have investigated whether SRIF receptors are 
present and functional in human bronchial smooth muscle. Reverse transcriptase- 
polymerase chain reaction (RT-PCR) analysis ofhBSMC total mRNA demonstrated the 
presence of the sst, receptor subtype, providing a molecular target for SRIF action. 
SRIF's functional effects on intracellular signaling were confirmed by Western blotting 
with phospho-specific antibodies for the extracellular regulated kinases 1/2 (ERKl/2). 
Using a nonpeptidyl sst, selective agonist, L-779,976, we demonstrated an acute 
inhibition (50 ± 5%) of basal ERKl/2 phosphorylation. In addition, L-779,976-treated 
hBSMC cell membranes showed a 2.4-fold increase in tyrosine phosphatase activity, 
which was abolished by the selective tyrosine phosphatase inhibitor sodium vanadate. 
Furthermore, a 48 h treatment with 100 nM L-779,976 suppressed hBSMC proliferation 
by 30%. Taken together, our results show that the hBSMC is a direct target of SRIF' s 
antiproliferative activity. We propose that SRIF's actions in controlling lung smooth 
muscle cell proliferation could prove therapeutically useful in chronic asthma where 
inappropriate hBSMC proliferation plays a role. 
Keywords: somatostatin, somatostatin receptors, inflammation, bronchial smooth muscle 
cells, extracellular regulated kinase, tyrosine phosphatase. 
5 
INTRODUCTION 
Asthma, characterized by airway hyperreactivity and airway structure remodeling, 
is thought to be the consequence of inflammation (Halayko and Amrani, 2003). Among 
the myriad of changes that take place within the bronchial walls of an asthmatic - 
subepithelial fibrosis, epithelial detachment, mucus gland hyperplasia, sub-mucosal 
myofibroblast hypertrophy, increased vascularization, and neuronal differentiation­ 
smooth muscle hypertrophy and hyperplasia play a dominant role in asthma (Holgate, 
2003; Jeffery, 2001; Woodruff et al, 2004). These changes within the walls of the 
airway, along with a host of inflammatory cytokines, are implicated in the exacerbation 
of airway hyperreactivity (Elias, 2000). Clearly any change to the growth or contractile 
function of airway smooth muscle would be an important contributor to the 
pathophysiology of asthma. 
Since the recognition that the presence of remodeled, non-specific, 
hyperresponsive airways are critical to the symptomology of asthma, there has been 
renewed interest in the investigation of bronchial smooth muscles cells to seek answers to 
fundamental questions. In vitro studies of airway myocytes have shown that G protein­ 
coupled receptor (GPCR) signaling and contractile force in human bronchial smooth 
muscle cells (hBSMC) can be augmented by inflammatory stimuli, both physical and 
chemical in nature (Amrani et al, 2004). In this regard, pro-inflammatory peptides such 
as Substance P and Neurokinin A, have long been-accepted as contributing to the 
expression of asthmatic symptoms through their ability to cause bronchoconstriction, 
neurogenic edema and inflammation. However the airway role of anti-inflammatory 
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peptides, such as somatostatin (somatotropin release inhibitory factor; SRIF) has not been 
explored. 
SRIF, initially discovered in the hypothalamus, is a potent inhibitor of growth 
hormone release (Brazeau et al, 1973). Since then, SRIF's spectrum of biological 
activities has grown steadily and today SRIF peptides are known to influence a range of 
secretory functions, including gastric acid secretion (Larsson et al, 1979), thyroid 
stimulating hormone effects (Singh et al, 2000), and insulin and glucagon secretion in the 
pancreas (Strowski et al, 2000). In the immune system, SRIF peptides have anti­ 
inflammatory effects on leukocyte function (Krantic, 2000), namely SRIF inhibition of 
leukocyte proliferation and cytokine synthesis (Elliot et al, 1998). 
At the cellular level, SRIF peptides activate a family of five highly homologous, 
G protein coupled receptors (sst, - sst-) that coexist in many tissues (Krantic et al, 2004; 
Reisine, 1995). SRIF modulates intracellular signaling by controlling membrane ion 
conductance and protein phosphorylation levels, in addition to decreasing cyclic 
nucleotide levels (Florio et al, 1996). Unifying SRIF's cellular actions is the control of 
cellular secretion and the suppression of cellular proliferation (Florio et al, 2003). 
Within the body, SRIF can be found in two forms: SRIF-14 and SRIF-28, 
consisting of 14 and 28 amino acids, respectively. Additionally, cortistatin is a related 
member of the SRIF peptide family, and may predominate in the immune system 
(Lichtenauer-Kaligis et al, 2004). Currently, SRIF-14 is considered to be the most 
widely expressed SRIF peptide and its presence can be readily detected in human serum. 
While the immunomodulatory effects of SRIF may account, in part, for its anti­ 
inflammatory properties, it is unknown whether SRIF also has direct effects on the 
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bronchial smooth muscle cell, and therefore a possible role in modulating asthma. SRIF 
and receptor immunoreactivity observed in a range of lung carcinomas suggest that SRIF 
may be active in lung physiology (Cattaneo et al, 1996). Furthermore, SRIF receptors 
may be up-regulated in inflammation, suggesting an immunomodulatory role for this 
peptide family (Krantic, 2000). 
Considering the bronchial smooth muscle cell's crucial involvement in asthma 
and a possible role for SRIF peptides and receptors on bronchial smooth muscle cells, we 
studied the role of SRIF and SRIF analogs on cultured human bronchial smooth muscle 
cells (hBSMC). In the current study, we show that SRIF acts through an endogenously 
expressed SRIF receptor to regulate hBSMC intracellular signaling pathways that are 
involved in cell proliferation. Our results indicate a possible anti-proliferative role for 
SRIF in hBSMC monolayers. 
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MATERIALS AND METHODS 
Cell culture 
hBSMC were purchased from Clonetics (Walkersville, MD), grown in S Growth 
Medium plus supplements at 37°C in the presence of 5% C02. Cells were maintained in 
T-75 cm2 flasks, or multiwell tissue culture dishes and allowed to recover for 72 h before 
the beginning of the experiment. 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
hBSMC mRNA was isolated using the Micro-FastTrack™ 2.0 mRNA Isolation 
Kit (Invitrogen Life Technologies, CA). 
cDNA synthesis and the polymerase chain reaction (PCR) were carried out using 
the mRNA, the Superscript One-Step RT-PCR system (Invitrogen Life Technologies, 
CA) with the appropriate oligonucleotide primer pairs (hsst1r&r-2f&r; Invitrogen Life 
Technologies, CA & hsst3r&r-Sf&r; Integrated DNA Technologies, Coralville, IA). Human 
SRIF receptor primer sequences are as follows 5' to 3 ' :  hsst.r = 
GCAACA TGCTCA TGCC, hsst., = GCGTTATCCGTCCAGG; hsstir = 
AGAGCCGTACTATGACCTGA, hsst-, = AGCCACTCGGA TTCCAGAG; hsst-, = 
TCATCTGCCTCTGCTACCTGC, hsstj, = GAGCCCAAAGAAGGCAGGCT; hssta- = 
CATGGTCGCT ATCCAGTGCA, hssta, = CTCAGAAGGTGGTGGTCCTG; hsst., = 
GCTCCTGGTGTTCGCGGACGT, hsst., = GAGGATGACCACGAAGAAGTAGAGG. 
RT-PCR reactions were performed in IX Reaction Mix buffer containing RT/Platinum 
Taq Mix, 10 nM forward primer (hsstlf-sf), 1 OnM reverse primer, (hsstir-sr), template 
RNA in a final volume 50 µ1. RT-PCR was performed using a Perkin Elmer Thermal 
Cycler 9600 (Perkin Elmer, MA). Samples were incubated at 50°C for 30 min followed 
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by 94°C for 2 min and the PCR amplification was carried out over 30 cycles of94°C for 
30 sec, 58°C for 30 sec, 72°C for 2 min, with a final extension step of 72°C for 5 min. 
RT-PCR products were resolved by agarose gel electrophoresis and stained with 
ethidium bromide (1 Oµg/mL). DNA products were visualized using a UV 
transilluminator (UVP, Inc., CA), and photo images were captured using Alphaimager 
3.3D (San Leandro, CA) computer software. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting 
Parallel cultures of hBSMC cells were cultured with serum-free basal medium 
(Opti-MEM, lnvitrogen Life Technologies) for 48 hand then incubated in the presence or 
absence of 100 nM SRIF-14 (Peninsula Labs, CA) for 15  min at 37°C. Cell lysates were 
prepared, sonicated and heated to 70°C for 10 min., resolved on NuPAGE 10% Bis-Tris 
gels (lnvitrogen Life Technologies, CA) electroblotted onto polyvinyldifluoride (PVDF) 
membranes and treated for 45 min in a blocking buffer containing 5% (w/v) of non-fat 
dehydrated milk. ER.Kl/2 were immunodetected with a 1 :  1000 dilution of antiphospho 
ER.Kl/2 antibodies (Cell Signaling, MA). The membrane associated immunoreactivity 
was then detected using a 1 :2000 dilution of a horseradish peroxidase-conjugated anti­ 
rabbit secondary antibody and detected using ECL chemiluminescence (Amersham, NJ). 
The resulting autoradiograph was scanned, quantified with NIH Image and expressed as 
integrated pixel density, as previously described (Badway et al., 2004). 
Tyrosine phosphatase assay 
hBSMC cultures were incubated in the presence or absence of 100 nM SRIF-14 
for 30 min. Cell cultures were washed in PBS and then lysed in a 50mM HEPES buffer 
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containing 0.5% Triton X-IOO, 10% glycerol (GibcoBRL), 2.5µM pepstatin A, 12.5µM 
leupeptin, 12.5µM aprotinin, 12.5µM bacitracin and 200nM polymethylsulfonyl fluoride. 
Lysates were centrifuged at 13,500 x g for 1 5  min at 6°C and the supernatant retained. 
Protein phosphatase assays were performed in a clear bottom, black sided 96 well 
dishes (Coming, Coming, NY). hBSMC cell lysate (approximately 65µg) was incubated 
with 1 OµM fluorescent phosphatase substrate, 6,8-difluoro-4-methylumberiferyll 
phosphate (DiF-MUP; Molecular Probes, OR) for IO min at 3TC with intermittent 
mixing in a CytoFluor 4000 fluorescent plate reader (Applied Biosystems, CA), with 
360nm excitation and 460nm emission filters. Parallel assays were conducted in the 
presence of IO µM Na3V04, an inhibitor of tyrosine phosphatase activity. The resulting 
data was analyzed with GraphPad Prism 4.0 and statistical significance was determined 
by analysis of variance (ANOVA), followed by a Neuman-Keuls post-test, with statistical 
significance defined asp< 0.05. 
Cell viability assay 
Cell viability assays were performed in 24-well plates with hBSM cells cultured 
in serum-free basal medium for 24 hand then incubated in the presence or absence of 
lOOnM L779,976 for 48 hours at 37°C. The samples were incubated with 1 µM calcein­ 
AM for 15 minutes prior to analysis in a CytoFluor 4000 fluorescent plate reader 
(Applied Biosystems; Blake, 2004). The resulting data was analyzed with GraphPad 
Prism 4.0 and statistical significance was determined by Student t-test (p< 0.05). 
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RESULTS 
Analysis ofhsst receptor expression using RT-PCR 
RT-PCR using SRIF receptor subtype specific oligonucleotides to analyze 
hBSMC demonstrated that the human bronchial smooth muscle cells express hsst, mRNA 
(Figure 1 ). The dominant amplified product appears as a 600 base pair (hsst-) band, 
indicating that the sst2 receptor subtype is present in these primary bronchial smooth 
muscle cells. While earlier studies have shown that several SRIF receptors are present in 
human lung, these results are the first to demonstrate a presence of the sst, receptor 
subtype in primary bronchial smooth muscle cells (Reubi et al, 2001). 
600 b p 7  
100bp7 
A. hsst 1 2 3 4 5 B. 
600bp 7 
100bp7 
hsst2 (BSMC) 
Figure 1. A. PCR amplification was performed on the sstl-5 receptor cDNAs. B. RT­ 
PCR amplification ofhBSMC receptor mRNA. The results are from a representative 
agarose gel ofhBSMC total mRNA amplified with SRIF receptor subtype specific 
oligonucleotides. Molecular weight markers (far left lane) appear in lanes in A and B as  
a  100 base pair DNA ladder. 
Western blot detection of phosphorylated ERKl/2 in hBSMC 
Mitogen-activated protein (MAP) kinases play a central role in mitogenesis and 
differentiation, controlling both activation magnitude and duration in bronchial smooth 
muscle cellular responses (Zhou and Hershenson, 2003). We examined the activation 
status of one of these protein kinases, the extracellular regulated kinases (ERKl/2) by 
Western blotting experiments, using a phospho-specific antibody against ERKl/2. In 
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parallel cultures maintained under static conditions, we showed that an acute treatment 
with 100 nM L-779,976 significantly decreased hBSMC basal levels of ERK.1/2 
phosphorylation (Figure 2). L-779,976 inhibited basal ERK.1/2 phosphorylation in 
hBSMC by 50 ± 5% when compared to parallel, untreated controls (Figure 2, p<0.05 
control versus L-779,976 treated), indicating a sst, receptor-mediated regulation of this 
enzyme. 
4 2 kD a -+ -  44 l<O a -+  
control L-779,976 
Control 10·7 M L-779,976 
0 
L-779,976 inhibits basal ERK1/2 phosphorylation 
100 
Figure 2. The sst, receptor agonist L-779,976 inhibits basal ERK.1/2 phosphorylation in 
hBSMC monolayers. Parallel cultures of hBSMC were incubated in the presence or 
absence of L-779,976. Cell lysates were resolved by gel electrophoresis, electroblotted 
and incubated with antiphospho-ERK.1/2 antibodies. Autoradiographs were quantified 
using NIH Image. The results represent the mean + SEM of three separate experiments 
(p< 0.05 between control and L-779,976 treated cells; Students t-test). The inset shows a 
representative autoradiograph. 
Determination of soluble tyrosine phosphatase activity 
SRIF receptors can couple to the activation of phosphotyrosine phosphatases in 
several cellular models, and this enzymatic activation is implicated in controlling cell 
proliferation (Florio and Schettini, 1996). To identify a possible role of the identified sst, 
receptor in controlling hBSMC cellular phosphatase activity, experiments using the 
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fluorescent substrate DiF-MUP were performed with hBSMC lysates prepared from 
untreated and treated (100 nM SRIF-14) cell monolayers. DiF-MUP provides a 
fluorescent measure of protein phosphatase activity, which when combined with an 
appropriate inhibitor can define the type of phosphatase activity being studied (Gee et al, 
1999). As shown in Figure 3,  1  OOnM L-779,976 increases membrane phosphatase 
activity in hBSMC monolayers by 2.4 fold over the untreated control group (p < 0.05; 
control versus L-779,976), while lOOnM SRIF-14 increases membrane phosphatase 
activity by 2.8 fold over the untreated control group (p < 0.05; control versus SRIF). In 
addition, co-incubation of the cell membranes with 10 µM sodium vanadate (Na3V04), a 
potent tyrosine phosphatase inhibitor, abolished greater than 90% of the enzymatic 
activity derived from both control and SRIF-14 treated cells (Figure3; p < 0.05 Na3V04 
versus SRIF-14 + Na3V04 ). The DiF-MUP phosphatase activity proved to be sensitive 
to Na3V04 inhibition, with both control and SRIF-14 treated cell membranes 
demonstrating an IC5o of inhibition in the low nanomolar concentration range ( data not 
shown). 
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Figure 3. SRIF ligands activate tyrosine phosphatase activity in hBSMC. hBSMC 
monolayers were either control or pretreated with 100 nM SRIF-14 or L-779.976 for 15  
min at 37°C. Phosphatase activity was measured with 50µM DiF-MUP for 10 min at 
37°C in a CytoFluor 4000 fluorescent plate reader. Parallel incubations were carried out 
with 10  µM sodium vanadate. The results were analyzed using GraphPad Prism 3 .0 and 
the data presented represent the mean + SEM of three separate experiments, each 
performed in triplicate. 
Determination of cell viability 
To further establish SRIF-14's role in dampening cell proliferation, assays were 
carried out in which hBSMC monolayers were incubated in the presence or absence of 
lOOnM L-779,976, followed by incubation with the fluorescence viability marker, 
calcein-AM. An earlier study has shown that the number of cells present directly 
correlate with the fluorescence signal as determined using a fluorescent plate reader 
(Blake, 2004). Figure 4 shows that L-779,976 treatment significantly reduced cell 
numbers by approximately 30%, suggesting that the SRIF agonist effectively suppressed 
hBSMC proliferation in our assay. 
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hBSMC Cell Viability Assay 
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Figure 4. L 779, 976 decreases BSMC cell number. hBSM cells were cultured in serum­ 
free basal medium in 24-well plates for 24 hand then incubated in the presence or 
absence of 100 nM L779, 976 for 48 hours at 37°C. The samples were incubated with 
calcein-AM for 15  minutes prior to analysis in a CytoFluor 4000 fluorescent plate reader 
(Applied Biosystems). L779, 976 reduced cell viability by approximately 30%. Student 
t-test, *p<0.05 
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DISCUSSION 
SRIF regulates intracellular signaling through actions on intracellular ion 
concentrations, cyclic nucleotides and protein phosphorylation levels (reviewed in 
Badway and Blake, 2005). In our experiments we used primary human bronchial smooth 
muscle cells (hBSMC) as a model system to assess SRIF-14 analogue actions, as these 
cells are thought to play a significant role in asthmatic airway remodeling, a significant 
component of chronic asthma (Halayko and Amrani, 2003]. 
We first established the SRIF receptor subtypes present in hBSMC, using RT­ 
PCR and oligonucleotides specific to hsst.«, The results of our RT-PCR amplification of 
total hBSMC RNA clearly revealed the presence of sst2• This finding is of considerable 
interest, since our study presents the first identification of the SRIF receptor subtype 
present in normal, isolated bronchial smooth muscles cells. 
Although SRIF receptors can couple to multiple intracellular signaling pathways 
(Badway and Blake, 2005), we were interested in examining whether the sst, receptor 
could control the growth of the hBSMC. MAP kinase activation plays a critical role in 
many cellular responses including proliferation and cell cycle progression (Taille et al, 
2003). Previous studies have demonstrated a role for SRIF and SRIF analogues in 
regulating MAP kinase pathways in a range of primary cells and cultured cell lines 
(reviewed in Dasgupta, 2004; Badway and Blake, 2005). In addition, it has been 
demonstrated that up-regulation and therefore activation of the MAP kinase ERK.1/2 
pathway can lead to the promotion of cell proliferation and cell cycle progression, and 
increased cell survival thereby protecting cells from apoptosis (Chang and Karin, 2001; 
Werry et al, 2005). After discovering SRIF receptor expression in hBSMC, we carried 
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out western blot experiments using ERK 1 /2 phospho-specific antibodies to determine 
SRIF's ability to modulate the MAP kinase pathway in hBSMC. Since the active kinase 
is phosphorylated our experiments showed that treatment with lOOnM L-779,976, the 
sst2 agonist, effectively reduces the ERK phosphorylation state within hBSMCs (Figure 
2). By inference, it is possible that SRIF functions in an anti-proliferative action to 
inhibit airway smooth cell expansion. This may be an important counter regulator of the 
hypertrophic response found in asthmatic airways (Zhou et al, 2004) 
In vitro fluorescence assays using a synthetic substrate (DiF-MUP) explored 
SRIF's intracellular signaling mechanism in hBSMC. Treatment ofhBSMC with 100 
nM L-779,976 or SRIF-14 increased DiF-MUP fluorescence in prepared cell membranes. 
Parallel experiments carried out in the presence of sodium vanadate, a potent tyrosine 
phosphatase inhibitor, abolished the DiF-MUP activity. These results suggest that the 
measured DiF-MUP activity results from activation of soluble tyrosine phosphatases. 
ERKl/2 is phosphorylated on tyrosine and threonine residues, it is possible that the 
increase in tyrosine phosphatase activity as a result of sst, receptor stimulation by SRIF- 
14 or L-779,976 treatments plays a role in the decrease in phospho-ERKl/2 levels. MAP 
kinase phosphatases (MKP), a group of dual specificity phosphatases, are members of a 
superfamily of protein tyrosine phosphatases (Tonks et al, 2001 ), and our data raise the 
possibility that some members of these hBSMC enzymes may be under SRIF-14 control. 
Since these results suggested that SRIF may function to inhibit proliferation and 
hinder cell survival in hBSMC, we performed a cell proliferation assay using the 
fluorescent marker calcein-AM (Blake, 2004). After treatment with 1 OOnM L- 779 ,976 
for 48 hours and subsequent calcein-AM staining, a 30% decrease in cell retained 
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fluorescence was measured as compared to control, untreated cells. Since calcein AM 
retention in the cellular monolayer directly correlates with viable cell number (Blake, 
2004), our results suggest that L-779,976-mediated inhibition of ERK.1/2 may have a 
direct effect on hBSMC growth and proliferation. 
Chronic inflammation, leading to airway remodeling and airway hyperreactivity, 
is the hallmark of asthma. The structural changes, including airway smooth muscle 
hypertrophy and hyperplasia, disrupt a number of homeostatic mechanisms in the lung. 
This includes disrupted homeostasis in the airway epithelium, subepithelial fibrosis, 
bronchial vascular remodeling, as well as the noted increase in airway smooth muscle 
mass (McKay et al 2002). While SRIF-14 and its analogues have been shown to regulate 
cellular homeostasis and exert anti-inflammatory effects in a number of cells and tissues, 
the current study provides the first evidence for possible SRIF inflammatory control in 
bronchial smooth muscle. 
Our results have shown that a SRIF analogue is capable of regulating hBSMC 
intracellular pathways that may be therapeutically important to inhibition of the structural 
remodeling found in asthma. Our results demonstrate for the first time the presence of an 
sst2 receptor subtype in hBSMC, implicated in controlling distinct intracellular signaling 
pathways, thereby implicating the body's endogenous SRIF peptide family in direct 
actions on bronchial smooth muscle. 
In order to further elucidate SRIF's anti-inflammatory effects on bronchial 
smooth muscle, it would be advantageous to measure SRIF's effects on ERK.1/2 
phosphorylation, tyrosine phosphatase activation, and cell viability in human bronchial 
smooth muscle cells obtained from asthmatic subjects. In addition, other intracellular 
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signaling pathways, including p38 and JAK-STAT have been studied in hBSMC (Simon 
et al, 2002) however, the effect of somatostatin on these kinase cascades remains to be 
seen. Such a parallel experiment would extend our knowledge of SRIF's ability to 
modulate inflammation in vitro. Ultimately, demonstration of the physiological results of 
SRIF administration would provide greater insight into the future therapeutic value of 
SRIF in asthma. 
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CONCLUSIONS 
In the current study, we establish the presence of a functionally active ssr, 
receptor in human bronchial smooth muscle cells. Our novel results show that L-779,976, 
an sst, selective analogue, is capable of regulating the ERKl/2 pathway, resulting in the 
deactivation of phosphorylated ERKl/2. Our data further postulates that SRIF-treatment 
causes an increase in protein tyrosine phosphatase activation, present in the membranes 
ofhBSMC, which may be responsible for the dephosphorylation ofERKl/2. Finally, we 
observed that treatment with a SRIF analogue could suppress cell viability by 
approximately 30%, suggesting a downregulation of hBSMC proliferation, a downstream 
target of ERK 112. These results suggest that SRIF and its analogues may play a role in 
preventing the hypertrophy of the airway via intracellular signaling in human bronchial 
smooth muscle cells. 
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